Adding venetoclax to fludarabine/busulfan RIC transplant for high risk MDS and AML is feasible, safe, and active.
Sign Up to like & getrecommendations! Published in 2021 at "Blood advances"
DOI: 10.1182/bloodadvances.2021005566
Abstract: Adding the selective BCL-2 inhibitor venetoclax to reduced intensity conditioning (RIC) chemotherapy (fludarabine and busulfan, FluBu2) may enhance anti-leukemic cytotoxicity and thereby reduce the risk of post-transplant relapse. This phase 1 study investigated the recommended… read more here.
Keywords: risk; high risk; transplant; fludarabine busulfan ... See more keywords
Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma.
Sign Up to like & getrecommendations! Published in 2023 at "Blood advances"
DOI: 10.1182/bloodadvances.2023009992
Abstract: Mantle cell lymphoma (MCL) is a rare, incurable hematological malignancy with a heterogenous presentation and clinical course. A wide variety of chemotherapy-based regimens are currently utilized in untreated patients. Several targeted or small molecule therapies… read more here.
Keywords: adding venetoclax; cell lymphoma; patients untreated; mantle cell ... See more keywords